BrainChild Bio raises $116M Series A for CNS cancer therapies

CAR T-cell therapy delivered close to the tumor

BrainChild Bio engineers immune cells to recognize tumor antigens and delivers them into cerebrospinal fluid through an implanted reservoir and catheter. The access point allows repeat infusions and is intended to address the challenge of reaching tumors behind the blood-brain barrier while reducing exposure elsewhere in the body.

The clinical-stage company is developing treatments for pediatric brain cancer and glioblastoma, central nervous system tumors with limited treatment options.

Use of funds

Support Phase 2 ILLUMINATE study of BCB-276 for DIPG

Continue development of BCB-214 for glioblastoma

Funding history

Sep 8, 2026Series A · This round$116M

Sources

Similar rounds

All Biotech rounds →

Aventix

Aventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.

€1.2MPre-seed · Sep 30, 2026

AnaCardio

AnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.

€62.5MSeries B · Sep 30, 2026

Aptadir Therapeutics

RNA therapeutics designed to restore expression of silenced genes

€40MSeed · Sep 29, 2026

MOYOM Biotech

Develops absorbable biomaterials and implantable medical devices for regenerative aesthetic treatments.

UndisclosedFinancing round · Sep 28, 2026